These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358 [TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease stratification by liver lipidomics. Vvedenskaya O; Rose TD; Knittelfelder O; Palladini A; Wodke JAH; Schuhmann K; Ackerman JM; Wang Y; Has C; Brosch M; Thangapandi VR; Buch S; Züllig T; Hartler J; Köfeler HC; Röcken C; Coskun Ü; Klipp E; von Schoenfels W; Gross J; Schafmayer C; Hampe J; Pauling JK; Shevchenko A J Lipid Res; 2021; 62():100104. PubMed ID: 34384788 [TBL] [Abstract][Full Text] [Related]
4. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis. Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102 [TBL] [Abstract][Full Text] [Related]
5. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994 [TBL] [Abstract][Full Text] [Related]
6. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. Loomba R; Quehenberger O; Armando A; Dennis EA J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585 [TBL] [Abstract][Full Text] [Related]
7. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590 [TBL] [Abstract][Full Text] [Related]
13. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease. Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365 [TBL] [Abstract][Full Text] [Related]
14. Concise review of lipidomics in nonalcoholic fatty liver disease. Béland-Bonenfant S; Rouland A; Petit JM; Vergès B Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065 [TBL] [Abstract][Full Text] [Related]
16. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. Mato JM; Alonso C; Noureddin M; Lu SC World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337 [TBL] [Abstract][Full Text] [Related]